# 1 Title:

# 2 Phenotypes of cough in children: a latent class analysis

3

# 4 Authors:

- 5 Maria Christina Mallet<sup>1,2</sup>, Eva SL Pedersen<sup>1</sup>, Ronny Makhoul<sup>1,2</sup>, Sylvain Blanchon<sup>3</sup>, Karin Hoyler<sup>4</sup>, Anja
- 6 Jochmann<sup>5</sup>, Philipp Latzin<sup>6</sup>, Alexander Moeller<sup>7</sup>, Nicolas Regamey<sup>8</sup>, SPAC Study Team<sup>9</sup>, Myrofora
- 7 Goutaki<sup>1,6</sup>, Ben D Spycher<sup>1</sup>, Claudia E Kuehni<sup>1, 6</sup>
- 8

# 9 Affiliations

10	1.	Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
11	2.	Graduate School for Health Sciences, University of Bern, Bern, Switzerland
12	3.	Dept Woman-Mother-Child, Service of Pediatrics, Pediatric Pulmonology and Cystic Fibrosis
13		Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
14	4.	Kinderpneumologie Horgen, Private Practice for Pediatric Pneumology, Horgen, Switzerland
15	5.	Department of Paediatric Pulmonology, University Children's Hospital Basel, Switzerland
16	6.	Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics,
17		Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
18	7.	Department of Respiratory Medicine, University Children's Hospital Zurich and Children's
19		Research Centre, University of Zurich, Zurich, Switzerland
20	8.	Division of Paediatric Pulmonology, Children's Hospital, Cantonal Hospital Lucerne,
21		Switzerland
22	9.	A list of the SPAC Study Team can be found in the acknowledgements section
23		
24	Corres	ponding author: Prof. Dr. med Claudia E. Kuehni, Institute of Social and Preventive Medicine,
25	Univer	sity of Bern, Mittelstrasse 43, 3012, Bern, Switzerland; Tel: +41 31 684 35 07; email:
26	<u>claudia</u>	.kuehni@ispm.unibe.ch
27		
20		
28		
29	Manus	cript: Words: 3440 /3500; Printed figures and tables: 7/8; Supplementary display items: 8
30	NOTE: T	his preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 31 Key words

32 allergy, childhood, clinical phenotypes, cough, latent class analysis, FeNO, respiratory

33	symptoms, spirometry, unsupervised learning
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

# 59 ABSTRACT (299/300 words)

Background: Distinguishing phenotypes among children with cough helps understand
underlying causes. Using a statistical data-driven approach, we identified cough phenotypes
and we aimed to validate them based on measurable traits, physician diagnoses, and
prognosis.

Methods: We used data from 531 children aged 5–16 years from the Swiss Paediatric 64 65 Airway Cohort—a multicentre clinical cohort of children seen in outpatient clinics since 2017. We included children with any parent-reported cough (i.e. cough without a cold, 66 cough at night, cough more than others, or cough longer than 4 weeks) without current 67 wheeze. We applied latent class analysis to identify phenotypes using 9 symptoms and 68 69 characteristics and selected the best model using the Akaike Information Criterion. We 70 assigned children to the most likely phenotype and compared the resulting groups with 71 regards to parental history, comorbidities, measurable traits, physician diagnoses, and prognosis after 1 year. 72

73 **Results:** Our analysis distinguished 4 cough phenotypes: 1. unspecific dry cough (25%); 2. 74 non-allergic infectious and night cough with snoring and otitis (4%); 3. allergic dry night 75 cough with snoring (9%); and 4. allergic cough (61%). Children with the allergic phenotype often had family or personal history of atopy and were diagnosed with asthma. Fractional 76 77 exhaled nitric oxide was highest for the allergic phenotype [median 17.9 parts per billion (ppb)] and lowest for the non-allergic infectious phenotype (median 7.0 ppb). Positive 78 allergy test results differed across phenotypes (p<0.001) and were most common among the 79 80 allergic (70%) and least common among the unspecific dry cough (31%) phenotypes.

- 81 Subsequent wheeze was thrice as high among the allergic than the unspecific dry cough
- 82 phenotype.
- 83 **Conclusion:** We distinguished 4 clinically-relevant cough phenotypes; they differed by
- 84 measurable traits, physician diagnoses, and prognosis. Although we excluded children with
- 85 current wheeze, most children belonged to allergy-related phenotypes and possibly need
- 86 allergy and asthma work-ups.

# 87 Three key messages

88	1.	Latent class analysis identified 4 cough phenotypes distinguished by measurable
89		traits, diagnoses, and prognosis.
90		
91	2.	Most children belonged to allergy-related phenotypes and possibly need allergy and
92		asthma work-ups.
93		
94	3.	Symptom-based cough phenotypes correlate with measurable traits and potentially
95		apply to all healthcare settings.

96

# 97 1. INTRODUCTION

Recurrent cough is a frequent symptom in paediatric care and the underlying aetiologies are 98 heterogeneous.<sup>[1-3]</sup> Most common causes of cough include respiratory tract infections and 99 asthma, yet many children cough in the absence of wheeze, colds, or obvious underlying 100 disease, which presents diagnostic challenges for physicians.<sup>[1, 3-5]</sup> Many causes have been 101 102 described for the latter group of children, ranging from upper airway cough syndrome caused by allergic and non-allergic rhinitis, asthma-like conditions and gastroesophageal 103 104 reflux to psychogenic and habit/tic cough disorders.<sup>[1, 6-10]</sup> Clinical guidelines for differential 105 diagnosis of cough among children are used to classify cough into aetiologies based on cough duration, dry versus wet cough, triggers, associated symptoms and diseases, and 106 measurable physiological traits, such as lung function and allergy tests. These guidelines are 107 usually based on expert opinions and involve some degree of overlap between diagnoses.<sup>[11-</sup> 108 <sup>13]</sup> Unsupervised learning methods, such as latent class analysis (LCA), are increasingly being 109 110 used as a more objective, data-driven approach to distinguish phenotypes of disease. Such methods are not limited by predefined categories and account for multiple disease 111 dimensions.<sup>[14, 15]</sup> Distinguishing phenotypes may lead to new hypotheses concerning 112 underlying aetiologies and mechanisms, ease diagnostic work-ups, guide targeted 113 management, and predict outcomes, such as respiratory symptoms.<sup>[15-17]</sup> 114 Although LCA is widely used to classify children with wheeze, asthma, or bronchiolitis, <sup>[18-25]</sup> 115 116 few have applied LCA to children presenting with recurrent cough.<sup>[15, 26-28]</sup> Present studies 117 were population-based, thus mainly included children with rather mild disease, many of whom had not seen a paediatric respiratory specialist for cough. In addition, most studies 118 were either focused on asthma and wheeze with little emphasis on cough—thus limiting 119 identification of cough phenotypes<sup>[15, 26, 27]</sup>—or included measurable physiological traits for 120

Page 6 of 22

121	phenotype definition, which limits use across healthcare settings with restricted or no
122	access to diagnostic tests. <sup>[15, 26]</sup> We aimed to identify phenotypes of cough in children
123	consulting physicians, using information that is readily available in all healthcare settings,
124	including primary care. Using data from a clinical population of children presenting with
125	cough without current wheeze, we applied LCA to a set of cough-related symptoms and
126	characteristics to identify and describe cough phenotypes. We further aimed to validate the
127	identified phenotypes by assessing their associations with clinically-relevant features,
128	including parent-reported information, paediatric pulmonologist diagnoses, measurable
129	physiological traits, and prognosis of respiratory symptoms 1 year later.

# 130 **2. METHODS**

# 131 **2.1 Study design and population**

132 The Swiss Paediatric Airway Cohort (SPAC) is a prospective clinical study integrated into the 133 routine care of 8 paediatric respiratory outpatient clinics and 2 paediatric practices across Switzerland. SPAC design and methods are described in detail elsewhere.<sup>[29]</sup> SPAC enrols 134 children aged 0–16 years referred by general practitioners or paediatricians for the 135 evaluation of common respiratory problems, such as cough, wheeze, and exercise-induced 136 symptoms. At time of referral, parents or guardians complete a baseline questionnaire 137 138 about respiratory symptoms, socio-demographic information, environmental exposures, 139 personal and family history, and comorbidities. One year after completing the baseline questionnaire and yearly thereafter, parents receive a follow-up questionnaire asking about 140 141 symptoms and treatments during the past 12 months. From hospital records, we retrieve information about results of diagnostic tests and paediatric pulmonologist diagnoses. The 142 Bern Cantonal Ethics Committee (Kantonale Ethikkomission Bern 2016-02176) approved the 143 study; parents and patients older than 14 years provided their written consent. 144

# 145 2.2 Inclusion criteria

146	We only included children aged 5–16 years at the time of visit because physiological traits,
147	such as lung function and allergies, are routinely measured for this age group. We included
148	all children with completed baseline parental questionnaires by December 31, 2020 who
149	indicated suffering from any recurrent cough. We used 4 validated and commonly used
150	questions about cough: "Does your child have a cough even without having a cold?" (cough
151	without a cold); <sup>[30]</sup> "In the last 12 months has your child had a dry cough at night, apart from
152	a cough associated with a cold or a chest infection?" (dry night cough); <sup>[31]</sup> "Do you think
153	your child coughs more than other children?" (cough more than others); <sup>[32]</sup> and "Has your
154	child had a cough in the past 12 months that lasted more than 4 weeks in a row?" (chronic
155	cough). We excluded children who reported wheeze in the past 12 months (current
156	wheeze), but not those who reported wheeze earlier in life (> 12 months ago) or with

#### 158 **2.3 Definition of indicator variables**

As indicator variables for the latent class model, we included the following 9 variables, all 159 160 reported during the last 12 months from the baseline questionnaire: frequency of colds ( $\geq$ 161 7/year), pneumonia, otitis media, regular snoring, rhino-conjunctivitis, dry night cough, type of cough (dry versus wet), duration of cough (> 2 months), and number of allergic cough 162 163 triggers, including pets, pollen, and house dust, ranging from 0 to 3 (Table S1). We selected 164 these cough-related symptoms and characteristics based on a consensus among authors as they were considered to be potential indicators of underlying aetiologies that can be easily 165 166 asked in all clinical settings, including primary care.

167

168

# 169 **2.4 Definition of variables to characterise and validate identified phenotypes**

170	We characterised and validated the identified phenotypes by comparing how these differed
171	according to a) parent-reported information, b) paediatric pulmonologist diagnoses, c)
172	results of measurable traits, and d) prognosis of respiratory symptoms 1 year later.
173	First, we compared the phenotypes with respect to exposure, family history, and
174	comorbidity information reported by parents in the baseline questionnaire. Second, we
175	compared the phenotypes with diagnoses given by paediatric pulmonologists who were
176	unaware of the LCA results. For simplicity, we grouped diagnoses into broad categories—
177	asthma, chronic cough, allergies, and others. A child could have several diagnoses. Appendix
178	S1 provides details of parent-reported information and physician diagnoses.
179	Third, we validated the identified phenotypes against measurable traits. We used body mass
180	index (BMI), spirometry, bronchodilator response (BDR), fractional exhaled nitric oxide
181	(FeNO), and allergy tests [skin prick test (SPT) and allergen specific IgE (sIgE)]. We converted
182	BMI into z-scores using reference values from the World Health Organisation. <sup>[33]</sup> For
183	spirometry, we transformed forced vital capacity (FVC), forced expiratory volume in the first
184	second (FEV1), FEV1/FVC, and the forced expiratory flow between the 25% and 75% of the
185	FVC (FEF 25–75) into z-scores using the Global Lung Initiative reference values. <sup>[34]</sup> We
186	defined a positive BDR test as an increase in FEV1 $\ge$ 12% (from baseline FEV1) after the use
187	of a short acting beta-agonist. FeNO measurements differed across clinics, with cut-offs
188	varying from 10 parts per billion (ppb) when using an offline method to 20–25 ppb for
189	online methods. <sup>[35]</sup> Thus, we first distinguished low versus high FeNO based on specified cut-
190	offs for each centre. We also assessed FeNO (measured online) as a continuous variable and
191	expressed in ppb. A positive allergy test was defined as either a positive SPT (mean wheal
192	size of $\geq$ 3mm) or a positive sIgE with values $\geq$ 0.35 kU/L. Since SPAC is an observational

study, physiological measurements are performed based on local protocols and indications 193 194 and not for all children. However, availability of measurements did not differ across phenotypes (Table S2). 195 Fourth, we compared prognosis 1 year later between phenotypes by looking at reported 196 197 cough without a cold, dry night cough, cough more than others, cough more than 4 weeks, and wheeze during the past 12 months. Parents of 360 (68%) children completed the first 198 year follow-up questionnaire and response rates did not differ by phenotype (Table S2). 199 2.5 Statistical analysis 200 To identify different phenotypes of cough, we fitted latent class models to the dataset 201 202 including the selected cough-related variables. To select number of latent classes 203 (interpreted here as phenotypes), we repeatedly fitted the model with the number of classes increasing stepwise from 2 to 10 and used Bayesian Information Criterion (BIC) and 204 Akaike Information Criterion (AIC) to select the optimal model.<sup>[36]</sup> These criteria favour 205 206 models that are parsimonious, i.e. have few model parameters (in our context this means fewer classes), while still achieving good model fit. For the final selection, we also took into 207 208 account interpretability and clinical relevance. We fitted models using the generalised 209 structural equation modelling function (gsem) in STATA. The dichotomised symptom variables were assumed to be binomially distributed within classes and the number of 210 211 allergic triggers as Poisson distributed. 212 For validation of phenotypes, we first assigned each individual to the phenotypes for which

it had the highest posterior membership probability.<sup>[14]</sup> We then compared the resulting
 groups with respect to parent-reported characteristics, paediatric pulmonologists diagnoses,
 measured traits and prognosis of respiratory symptoms after 1 year. We tested differences

- 216 between phenotypes using chi-squared and Fisher exact tests for categorical variables. For
- 217 non-normally distributed continuous variables we used Kruskal Wallis tests.
- 218 We recoded missing values for questions about symptoms as "no" since we assumed absent
- or mild symptoms when parents have not answered "yes" (Table S1). We performed all
- analyses in STATA (Version 15.1, StataCorp, TX, USA).

# 221 **3. RESULTS**

- 222 **3.1 Characteristics of study population**
- 223 Our analysis included 531 children with median age 11 years (interquartile range 8–13)
- (Figure S1, Table 1). Parents of 446 (84%) children reported cough without a cold, 289 (54%)
- cough more than others, 276 (52%) dry night cough, and 215 (40%) cough more than 4

226 weeks.

# 227 3.2 Description of phenotypes

Results of BIC and AIC were discordant: the lowest BIC indicated a model with 2 phenotypes

- and the lowest AIC a model with 4 phenotypes (Table S3). Since identifying cough
- phenotypes using LCA is exploratory, we present the model with 4 phenotypes which we
- think is more clinically-relevant, assuming there are more than 2 underlying causes for
- recurrent cough among children<sup>[13]</sup>. We summarise class size, main characteristics, and
- summary labels of the 4 phenotypes in the textbox, Figure 1, and Table S4.

# 4 cough phenotypes identified by latent class analysis (Details in Table S4)

# Phenotype 1: Unspecific dry cough (25%)

Children belonging to this phenotype reported few respiratory infections or allergic symptoms. Cough was described as mostly dry for half of the children without any other distinct characteristics.

# Phenotype 2: Non-allergic infectious and night cough with snoring and otitis (4%)

Frequent colds and pneumonia were more frequently reported than in other phenotypes. Children in this phenotype typically reported otitis media, night cough, and snoring. None had rhino-conjunctivitis, hardly any reported allergic triggers for cough, and cough was rarely reported as dry.

# Phenotype 3: Allergic dry night cough with snoring (9%)

Night cough, snoring, dry cough, and cough lasting more than two consecutive months were typical for this phenotype. Rhino-conjunctivitis and allergic cough triggers were much more commonly reported compared with phenotypes 1 and 2.

# Phenotype 4: Allergic cough (61%)

Nearly two-thirds of children were in this phenotype with highest probabilities of rhinoconjunctivitis and highest mean number of reported allergic triggers for cough. Very few colds, pneumonia, or otitis media were reported. The probability of reporting night cough and snoring was half of phenotype 3.

235 For completeness, we also present the model with 2 phenotypes in Table S5; it identified a 236 larger phenotype (73% of children) with allergic features (rhino-conjunctivitis, allergic 237 triggers), as the four-class model, and a smaller, less specific phenotype. 238 3.3 Validation of identified phenotypes Parent-reported characteristics, paediatric pulmonologist diagnoses, measurable traits, and 239 respiratory prognosis varied between the different phenotypes. Children with phenotype 2 240 were more often male (72%) and younger (median age: 7 years) compared with other 241 242 phenotypes (Table 2). Family history of asthma and hay fever and atopy-related 243 comorbidities, such as previous wheeze, physician-diagnosed asthma, hay fever, and 244 eczema, were reported for all phenotypes but were most common among children with phenotype 4 (allergic cough). 245 Paediatric pulmonologist diagnoses differed across the 4 phenotypes (Table 3). Asthma 246 diagnosis was most frequent in phenotype 4 (48%), followed by phenotype 1 (26%), 247 phenotype 3 (20%), and phenotype 2 (6%). Phenotype 3 contained the highest proportion of 248 249 children with a specific cough diagnosis (33%) by a paediatric pulmonologist, whilst in 250 phenotype 4 this number was smallest (8%). Children with phenotype 4 more often received 251 a diagnosis of rhinitis/rhino-conjunctivitis and allergic sensitisation/atopy. Regarding measurable traits, BMI did not differ across the 4 phenotypes (p=0.161) (Table 4). 252 Median z-scores of spirometry parameters (FCV, FEV1/FVC, and FEF25-75) were lowest for 253 254 phenotype 2 and highest for phenotype 3 (Table 4, Figures 2A and S2). Fewer than half the 255 children had a BDR test done and among those, the proportion with a positive BDR test did 256 not differ across phenotypes (p=0.406). FeNO values differed across groups (p<0.001) being 257 highest among children with phenotype 4 [17.9 ppb, 95% confidence interval (CI) 15.6–19.5]

and lowest for children with phenotype 2 (7.0 ppb, 95% CI 5.0–17.7) (Table 4, Figure 2B).

- 259 Similarly, positive allergy tests differed across phenotypes (p< 0.001) and were more
- common among children with phenotype 4 (70%, 95% CI 64–76), and relatively rare for
- 261 children with phenotype 1 (31%, 95% CI 23–41).
- 262 Regarding prognosis after 1 year, overall, cough was less often reported at follow-up (Figure
- 3) compared with baseline (Table 1). Children with phenotype 3 more often reported cough
- without a cold (66%), cough more than others (52%), and cough more than 4 weeks (24%)
- compared with children in other phenotypes (Figure 3). Night cough was more prevalent for
- children with phenotype 2 (57%) followed by children with phenotype 3 (41%). Wheeze was
- reported among 78 (22%) children and the proportion differed across the 4 phenotypes
- 268 (p=0.005). Children with phenotype 4 wheezed almost 3 times more after 1 year compared
- with children in phenotype 1.

# 270 **4. DISCUSSION**

Our study applied LCA to identify phenotypes in children who cough without wheeze. We
applied this method to a set of parent-reported cough-related symptoms and characteristics
in a clinical-based study. We identified 4 cough phenotypes with the allergic cough
phenotype as dominant. Upon validating the identified phenotypes, we found they differed
with respect to parent-reported information about family histories and comorbidities,
paediatric pulmonologist diagnoses, measurable traits, and respiratory prognosis 1 year

277 later.

# 278 4.1 Strengths and limitations

279 Ours is the first study identifying cough phenotypes in a clinical cohort of children by

applying a data-driven unsupervised learning approach to a wide range of cough symptoms

and characteristics. We used broad inclusion criteria—answering positively to any question 281 about cough—for our study population, which minimised the risk of missing some 282 phenotypes. In a previous population-based study, we found only a partial overlap between 283 positive answers to different cough questions, which likely reflects the existence of 284 subgroups of children with differences in underlying pathophysiology.<sup>[37]</sup> For phenotype 285 definitions, we used only cough-related symptoms and characteristics easily collected in 286 primary care settings to make our results applicable to all healthcare settings. Lastly, we 287 288 used different ways to validate the 4 phenotypes, including parent-reported information, paediatric pulmonologist diagnoses, measurable traits, and 1-year prognosis to help 289 ascertain clinical relevance. Our study also has some limitations. First, despite our use of a 290 data-driven approach, selecting variables to include in the model always involves some 291 degree of subjectivity. Second, our baseline questionnaire lacked information about signs 292 293 and symptoms of some possible aetiologies of cough, such as gastroesophageal reflux and 294 psychogenic and habit/tic cough, which thus could not serve as indicator variables to build the latent class model. Third, our study population is mainly representative of German- and 295 French-speaking families in Switzerland and includes few recent immigrants. Finally, we did 296 not externally validate our findings among an independent clinical population of children— 297 298 an interest for future studies to determine if we identify similar phenotypes. However, we are unaware of a similar study for validation. 299

300 4.2 Comparison with other studies

Our study is the first of its type to use LCA for identifying cough phenotypes among a clinical
 population of children. We cannot fully compare our findings with population-based studies
 also using LCA or similar clustering techniques to distinguish cough phenotypes.<sup>[15, 26-28, 38]</sup>
 We provide a summary of study designs and populations, inclusion criteria, indicator

Page 15 of 22

variables, identified phenotypes/trajectories, and validation processes from existing studies 305 306 in Table S6. Spycher et al. and Weinmayr et al. included children who wheeze and used mostly wheeze-related symptoms with only few questions about cough as indicator 307 variables in the LCA. <sup>[15, 27]</sup> Spycher et al. also included physiological measurements as 308 indicator variables in the LCA.<sup>[15]</sup> In contrast, we excluded children who wheezed, and as 309 indicator variables, we used a rich set of only cough-related questions allowing us to identify 310 more cough phenotypes and to describe them in more detail. 311

312 Divaret-Chauveau et al. and Rancière et al. investigated cough without cold and dry night cough trajectories, respectively.<sup>[28, 38]</sup> Both studies used only cough questions collected at 313 different time points to define cough trajectories/patterns, but they included children who 314 wheeze; and the children were also younger (Table S6). In an analysis stratified by presence 315 or absence of wheeze, Divaret-Chauveau et al. found physician-diagnosed asthma reported 316 among a small proportion of children in all cough trajectories (2 to 12%) even in the absence 317 of wheeze.<sup>[28]</sup> Rancière et al. also reported physician-diagnosed asthma ever in all cough 318 patterns (7 to 26%) but this included children who wheeze.<sup>[38]</sup> In our study, parent-reported, 319 physician-diagnosed asthma ever was also reported in all identified cough phenotypes, yet 320 in much higher proportions (22 to 55%). This might be explained by the difference in study 321 populations, since children visiting respiratory outpatient clinics likely present with more 322 severe respiratory problems than children from the general population. 323

324

4.3 Interpretation and implication of findings

Our study distinguished 4 phenotypes of cough among children. Based only on parent-325 reported characteristics, distinctions between different phenotypes were not clear-cut, yet 326 327 reflect the realities and difficulties of clinical practice when trying to establish underlying

328	aetiologies of cough based on history alone with further examinations usually required.
329	Nevertheless, interesting and clinically-relevant patterns, such as cough driven by allergies
330	and upper airway pathology, correlating with several parent-reported characteristics,
331	paediatric pulmonologist diagnoses, measurable traits and prognosis, emerged from the
332	latent class model.
333	Interestingly, most children (70%) had phenotypes related to allergy (Phenotypes 3 and 4).
334	In terms of clinical implications, children who cough with allergic symptoms possibly need
335	allergy and asthma work-ups even in absence of reported wheeze. Divaret-Chauveau et al.
336	also concluded as such; they found an association between different cough trajectories and
337	asthma/allergic rhinitis. <sup>[28]</sup> Similarly, Rancière et al. found an association between children
338	with rising cough patterns—late and persistent coughers—and allergic comorbidity,
339	including asthma, and atopy, independent of the presence of wheeze. <sup>[38]</sup>
339 340	including asthma, and atopy, independent of the presence of wheeze. <sup>[38]</sup> Additionally, the relatively high proportion of children reporting wheeze at follow-up
340	Additionally, the relatively high proportion of children reporting wheeze at follow-up
340 341	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma
340 341 342	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often
340 341 342 343	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of
340 341 342 343 344	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of reporting wheeze at follow-up was higher among children of the persistent cough
340 341 342 343 344 345	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of reporting wheeze at follow-up was higher among children of the persistent cough phenotype compared with the transient cough phenotype (25% vs 10%). <sup>[15]</sup> Rancière et al.
<ul> <li>340</li> <li>341</li> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> </ul>	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of reporting wheeze at follow-up was higher among children of the persistent cough phenotype compared with the transient cough phenotype (25% vs 10%). <sup>[15]</sup> Rancière et al. found prevalence of wheeze at follow-up lowest among preschool children with infrequent
340 341 342 343 344 345 346 347	Additionally, the relatively high proportion of children reporting wheeze at follow-up (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma work-ups. Our statistical model identified specific groups of children who more often develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of reporting wheeze at follow-up was higher among children of the persistent cough phenotype compared with the transient cough phenotype (25% vs 10%). <sup>[15]</sup> Rancière et al. found prevalence of wheeze at follow-up lowest among preschool children with infrequent night cough (4%) compared with transient (8%) and rising pattern (consisting of late and

350

351	Another interesting finding of our study is the identification of 2 cough phenotypes
352	potentially driven by upper airway problems—1 allergic (phenotype 3) and 1 non-allergic
353	(phenotype 2). The presence of night cough and snoring, long duration of cough, and rhino-
354	conjunctivitis in phenotype 3 suggests house dust mite allergy. Children with phenotype 2
355	also had a high probability of night-time cough and snoring, yet in contrast to children with
356	phenotype 3, without an allergic component, with more frequent infections (colds,
357	pneumonia, otitis), and rarely reported dry cough. Phenotype 2 possibly represents children
358	with recurrent upper airway infections and adenoid hypertrophy or postnasal rhinorrhoea—
359	a small group (4% of children) perhaps restricted by our study population of children aged 5
360	years and older when respiratory infections become less common. <sup>[10]</sup> This group also had
361	the lowest estimated median lung function parameters but the number of children in this
362	group was small and estimates were subject to much uncertainty.
363	The second largest group (phenotype 1: unspecific dry cough) possibly represents children
364	with the so-called <i>non-specific isolated cough</i> —a "dry cough in the absence of identifiable
365	respiratory or known aetiology." <sup>[39]</sup> This group of children seems to have a more transient
366	cough, as compared with the other phenotypes, their prognosis after 1 year was better with
367	less cough and less wheeze.

# 368 **5. CONCLUSION**

The 4 cough phenotypes we identified by LCA revealed interesting clinical patterns, which may be helpful in clinical settings. Most children (70%) had a phenotype associated with allergies. Thus, most children who cough may benefit from allergy and asthma diagnostic work-ups even in absence of reported wheeze.

#### 373 AUTHOR CONTRIBUTIONS

- 374 CK, ESLP, and MG designed and set-up the SPAC study. CK, MCM, ESLP, and MG
- 375 conceptualised the analysis with input from SB, KH, AJ, PL, AM, NR, and BDS. SB, KH, AJ, PL,
- 376 AM, NR, and CK recruited participants for the study. MCM, ESLP, and RM collected and
- 377 entered data. MCM performed statistical analyses. BDS and ESLP supported statistical
- analyses. MCM drafted the manuscript with substantial input from CK. All authors
- interpreted the data, critically reviewed the manuscript, and approved the final version of
- the manuscript.
- 381

## 382 ACKNOWLEDGEMENTS

383 We thank the families who took part in the SPAC study, the research assistants (Natalie

384 Messerli, Gia Thu Ly, Labinata Gjokaj and Meret Ryser) for helping with data collection and

data entry, Kristin Marie Bivens, PhD (Institute of Social and Preventive Medicine, University

of Bern) for her editorial contribution, PedNet Bern for supporting data collection in Bern,

387 and the members of the SPAC study team.

388 SPAC study team members include D. Mueller-Suter, P. Eng, and A. Kuhn (Canton Hospital

Aarau, Aarau, Switzerland); U. Frey, J. Hammer, A. Jochmann, D. Trachsel, and A. Oettlin

390 (University Children's Hospital Basel, Basel, Switzerland); P. Latzin, C. Abbas, M. Bullo, O.

391 Fuchs, E. Kieninger, I. Korten, L. Krüger, B. Seyfried, F. Singer, and S. Yammine, C.de Jong

392 (University Children's Hospital Bern, Bern, Switzerland); C. Casaulta and P. Iseli (Children's

393 Hospital Chur, Chur, Switzerland); K. Hoyler (private pediatric pulmonologist, Horgen,

- 394 Switzerland); S. Blanchon, S. Guerin, and I. Rochat (University Children's Hospital Lausanne,
- Lausanne, Switzerland); N. Regamey, M. Lurà, M. Hitzler, A. Clavuot, K. Hrup, and J. Stritt
- 396 (Canton Hospital Lucerne, Lucerne, Switzerland); J. Barben (Children's Hospital St Gallen, St

- 397 Gallen, Switzerland); O. Sutter (private pediatric practice, Worb, Bern, Switzerland); A.
- 398 Moeller, A. Hector, K. Heschl, A. Jung, T. Schürmann, L. Thanikkel, and J. Usemann
- 399 (University Children's Hospital Zurich, Zurich, Switzerland); and C.E. Kuehni, C. Ardura-
- 400 Garcia, D. Berger, T.Krasnova, R. Makhoul, M.C. Mallet, E. Pedersen, and M. Goutaki
- 401 (University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland).

#### 402 FUNDING INFORMATION

- 403 The Swiss National Science Foundation (SNF Grants: SNF 320030\_182628 & SNF
- 404 320030\_212519) funded the study. Myrofora Goutaki is funded by an SNF Ambizione
- 405 Fellowship (PZ00P3\_185923).

#### 406 CONFLICT OF INTEREST

- 407 MCM, ESLP, RM, AJ, MG, BDS, and CK have nothing to disclose. SB reports
- 408 meeting/travelling fees from OM Pharma and Novartis—all outside the submitted work. KH
- 409 reports personal fees from Astra Zeneca—all outside the submitted work. PL reports
- 410 personal fees from OM Pharma, Polyphor, Santhera, Vertex, Vifor, Sanofi Aventis, and
- 411 grants from Vertex—all outside the submitted work. AM reports personal fees from Vertex,
- 412 OM Pharma, Astra Zeneca, and grants from Vertex— all outside the submitted work. NR
- 413 reports personal fees from OM Pharma, Astra Zeneca, Schwabe Pharma, and Sanofi—all
- 414 outside the submitted work.

# 415 DATA AVAILABILITY STATEMENT

- 416 The data supporting our study findings are available on reasonable request from the
- 417 corresponding author.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.09.23287047; this version posted March 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 418 REFERENCES

419 Chang AB, Robertson CF, Van Asperen PP, Glasgow NJ, Mellis CM, Masters IB, et al. A 1. 420 multicenter study on chronic cough in children : burden and etiologies based on a standardized 421 management pathway. Chest. 2012;142(4):943-50.

422 2. Marchant JM, Newcombe PA, Juniper EF, Sheffield JK, Stathis SL, Chang AB. What is the 423 burden of chronic cough for families? Chest. 2008;134(2):303-9.

424 3. Shields MD, Bush A, Everard ML, McKenzie S, Primhak R. BTS guidelines: Recommendations 425 for the assessment and management of cough in children. Thorax. 2008;63 Suppl 3:iii1-iii15.

426 Cash H, Trosman S, Abelson T, Yellon R, Anne S. Chronic cough in children. JAMA Otolaryngol 4. 427 Head Neck Surg. 2015;141(5):417-23.

428 De Benedictis FM, Selvaggio D, De Benedictis D. Cough, wheezing and asthma in children: 5. 429 lesson from the past. Pediatric Allergy and Immunology. 2004;15(5):386-93.

430 Gao F, Gu Q-L, Jiang Z-D. Upper airway cough syndrome in 103 children. Chinese Medical 6. 431 Journal. 2019;132(6):653-8.

432 7. Asilsoy S, Bayram E, Agin H, Apa H, Can D, Gulle S, et al. Evaluation of chronic cough in 433 children. Chest. 2008;134(6):1122-8.

434 8. Gedik AH, Cakir E, Torun E, Demir AD, Kucukkoc M, Erenberk U, et al. Evaluation of 563 435 children with chronic cough accompanied by a new clinical algorithm. Ital J Pediatr. 2015;41:73.

- 436 9. Yu X, Kong L, Jiang W, Dai Y, Wang Y, Huang L, et al. Etiologies associated with chronic cough 437 and its clinical characteristics in school-age children. Journal of thoracic disease. 2019;11(7):3093-438 102.
- 439 10. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. Evaluation and 440 outcome of young children with chronic cough. Chest. 2006;129(5):1132-41.

441 11. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-442 based clinical practice guidelines. Chest. 2006;129(1 Suppl):260s-83s.

443 12. Chang AB, Oppenheimer JJ, Irwin RS. Managing Chronic Cough as a Symptom in Children and 444 Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2020;158(1):303-29.

445 13. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS 446 guidelines on the diagnosis and treatment of chronic cough in adults and children. The European 447 respiratory journal. 2020;55(1).

448 14. Mori M, Krumholz HM, Allore HG. Using Latent Class Analysis to Identify Hidden Clinical 449 Phenotypes. JAMA. 2020;324(7):700-1.

450 Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of 15. 451 childhood wheeze and cough using latent class analysis. Eur Respir J. 2008;31(5):974-81.

452 Ross MK, Eckel SP, Bui AAT, Gilliland FD. Asthma clustering methods: a literature-informed 16. 453 application to the children's health study data. J Asthma. 2022;59(7):1305-18.

454 Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are they real? Clin 17. 455 Exp Allergy. 2010;40(8):1130-41.

456 18. Lee E, Lee SH, Kwon JW, Kim YH, Yoon J, Cho HJ, et al. Persistent asthma phenotype related 457 with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. BMC Pulm Med. 2017;17(1):45. 458

- 459 Brew BK, Chiesa F, Lundholm C, Örtqvist A, Almqvist C. A modern approach to identifying 19. 460 and characterizing child asthma and wheeze phenotypes based on clinical data. PLoS One. 461 2019;14(12):e0227091.
- 462 20. Oksel C, Granell R, Haider S, Fontanella S, Simpson A, Turner S, et al. Distinguishing Wheezing 463 Phenotypes from Infancy to Adolescence. A Pooled Analysis of Five Birth Cohorts. Ann Am Thorac 464 Soc. 2019;16(7):868-76.
- 465 21. Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackson DJ, Szefler SJ, Beigelman A, et al.
- Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and 466
- Utility in Prediction of Future Exacerbation. J Allergy Clin Immunol Pract. 2019;7(3):915-24.e7. 467

medRxiv preprint doi: https://doi.org/10.1101/2023.03.09.23287047; this version posted March 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

468 22. Fitzpatrick AM, Bacharier LB, Jackson DJ, Szefler SJ, Beigelman A, Cabana M, et al. 469 Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class 470 Analysis and Association with 1-Year Outcomes. J Allergy Clin Immunol Pract. 2020;8(8):2617-27.e4. 471 23. Ferrante G, Fondacaro C, Cilluffo G, Dones P, Cardella F, Corsello G. Identification of 472 bronchiolitis profiles in Italian children through the application of latent class analysis. Ital J Pediatr. 473 2020;46(1):147. 474 24. Niu H, Chang AB, Oguoma VM, Wang Z, McCallum GB. Latent class analysis to identify clinical 475 profiles among indigenous infants with bronchiolitis. Pediatr Pulmonol. 2020;55(11):3096-103. 476 25. Petrarca L, Nenna R, Di Mattia G, Frassanito A, Castro-Rodriguez JA, Rodriguez Martinez CE, 477 et al. Bronchiolitis phenotypes identified by latent class analysis may influence the occurrence of 478 respiratory sequelae. Pediatr Pulmonol. 2022;57(3):616-22. 479 Spycher BD, Silverman M, Pescatore AM, Beardsmore CS, Kuehni CE. Comparison of 26. 480 phenotypes of childhood wheeze and cough in 2 independent cohorts. J Allergy Clin Immunol. 481 2013;132(5):1058-67. 482 27. Weinmayr G, Keller F, Kleiner A, du Prel JB, Garcia-Marcos L, Batllés-Garrido J, et al. Asthma 483 phenotypes identified by latent class analysis in the ISAAC phase II Spain study. Clin Exp Allergy. 484 2013;43(2):223-32. 485 28. Divaret-Chauveau A, Mauny F, Hose A, Depner M, Dalphin ML, Kaulek V, et al. Trajectories of 486 cough without a cold in early childhood and associations with atopic diseases. Clin Exp Allergy. 2022. 487 Pedersen ESL, de Jong CCM, Ardura-Garcia C, Barben J, Casaulta C, Frey U, et al. The Swiss 29. 488 Paediatric Airway Cohort (SPAC). ERJ Open Res. 2018;4(4). 489 Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir 30. 490 Dis. 1978;118(6 Pt 2):1-120. 491 31. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of 492 Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995;8(3):483-91. 493 Clifford RD, Radford M, Howell JB, Holgate ST. Prevalence of respiratory symptoms among 7 32. 494 and 11 year old schoolchildren and association with asthma. Arch Dis Child. 1989;64(8):1118-25. 495 33. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO 496 growth reference for school-aged children and adolescents. Bull World Health Organ. 497 2007;85(9):660-7. 498 34. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference 499 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir 500 J. 2012;40(6):1324-43. 501 Araya-Cloutier CV, J; Van de Schans, M; Hageman, J; Schaftenaar, G. ATS/ERS 35. 502 recommendations for standardized procedures for the online and offline measurement of exhaled 503 lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 504 2005;171(8):912-30. 505 Weller BEB, N.K; Faubert, S.J. Latent Class Analysis: A Guide to Best Practice. Journal of Black 36. 506 Pyschology. 2020;46(4):287-311. 507 37. Mallet MCM, R; Pedersen, E.S.L; Ardura-Garcia, C; Gaillard, E.A; Latzin, P; Moeller, A; Kuehni, 508 C.E. Prevalence of childhood cough in epidemiological studies depends on the question used: 509 findings from two population-based studies. Swiss Med Wkly. 2023; 153:40044. 510 Rancière F, Nikasinovic L, Momas I. Dry night cough as a marker of allergy in preschool 38. 511 children: the PARIS birth cohort. Pediatr Allergy Immunol. 2013;24(2):131-7. 512 39. Chang AB. Chronic non-specific cough in children. Paediatrics and Child Health. 513 2008;18(7):333-9.

514


# **Tables and Figures**

	N (%)
Sociodemographic and environmental exposure	
Male sex	314 (59)
Age, years (median, IQR)	11 (8–13)
Overweight or obesity based on BMI z-scores (N=521)	125 (24)
Swiss nationality	436 (82)
Parental highest education level	
Maternal tertiary (N=511)	149 (29)
Paternal tertiary (N=504)	203 (40)
Exposure to tobacco smoke (N=498)	142 (29)
Parental history	
Asthma or asthma inhaler use	191 (36)
Hay fever	247 (47)
Chronic cough	73 (14)
Comorbidities ever in life	
Previous wheeze	223 (42)
Physician-diagnosed asthma	245 (46)
Hay fever	222 (42)
Physician-diagnosed eczema	112 (21)
Cough symptoms and characteristics during the past 12 months	
Dry night cough	276 (52)
Cough without a cold	446 (84)
Cough more than others	289 (54)
Cough duration > 4 weeks	215 (40)
Cough duration > 2 months	79 (15)
Cough type	( )
Mostly dry	253 (48)
Mostly wet	53 (10)
Both dry and wet	221 (42)
Cough triggered by any aero-allergens (pollen, house dust, animals)	318 (60)
Other symptoms in the past 12 months	
Number of colds $\geq$ 7/year	61 (11)
Otitis media	47 (9)
Pneumonia	31(6)
Rhino-conjunctivitis	195 (37)
Snoring (without cold/almost always)	186 (35)

Table 1: Characteristics of study population included in the latent class analysis at baseline (N=531)

IQR: Interquartile range, BMI: Body Mass Index, we calculated BMI z-scores using reference values from the World Health Organisation; Parental history, comorbidities ever, cough and other symptoms are parent-reported.

**Figure 1:** Estimated class sizes (in brackets)\* and estimated probabilities of cough-related symptoms and characteristics of the four-class model identified by latent class analysis based on the lowest Akaike Information Criterion (N=531)



\*The width of the lines represents the size of the classes, i.e. the proportion of children in the different classes. The estimated probabilities which can take values from 0 to 1 and represent the probability of answering 'yes' for the dichotomous indicators variables (frequent colds  $\geq$  7, pneumonia, otitis media, night cough, rhino-conjunctivitis, snoring, mostly dry cough, cough > 2 months) for each of the 4 classes, while the estimated mean which can take values from 0 to 3 represents the average number of allergic cough triggers for each of the 4 classes.

**Table 2:** Socio-demographic characteristics, parental smoking, family history, and comorbidities for the 4 cough phenotypes (N=531)

Class	1		2		3		4		
Class description	ription Unspecific dry		Non-allergic		Allergic dry night		Allergic cough		
		cough		ous and night	cough	with snoring			
			-	with snoring					
				nd otitis					
		(N=145)		(N=18)		(N=45)		(N=323)	
	Ν	% (95%CI)	Ν	% (95%CI)	Ν	% ( 95%CI)	Ν	% (95%CI)	<i>p</i> - value
Sex (Male)	78	54 (46–62)	13	72 (48–88)	24	53 (39–67)	199	62 (56–67)	0.218
Age, years (median)	145	10 (9–11)	18	7 (7–10)	45	9 (8.0–10)	323	11 (11–12)	<0.001*
Swiss nationality	125	86 (80–91)	15	83 (59–95)	29	64 (50–77)	267	83 (78–86)	0.010
Parental tertiary									
education									
Maternal	43	31 (23–39)	4	24 (9–49)	20	44 (31–59)	82	27 (22–32)	0.092
Paternal	49	35 (27–43)	4	27 (10–53)	20	45 (31–60)	130	43 (37–48)	0.239
Parental smoking	38	29 (22–37)	6	33 (16–57)	12	27 (16–42)	86	28 (23–34)	0.966
Parental history									
Asthma	41	28 (22–36)	6	33 (16–57)	11	24 (14–39)	133	41 (36–47)	0.017
Hay fever	48	33 (26–41)	9	50 (28–72)	18	40 (27–55)	172	53 (48–59)	0.001
Chronic cough	19	13 (9–20)	2	11 ( 3–35)	6	13 (6–27)	46	14 (11–19)	0.973
Comorbidities ever									
Previous wheeze	37	26 (19–33)	5	28 (12–52)	8	18 (9–32)	173	54 (48–59)	<0.001
Physician-	51	35 (28–43)	4	22 (9–47)	12	27 (16–41)	178	55 (50-60)	<0.001
diagnosed asthma ever									
Hay fever	13	9 (5–15)	1	6 (1–31)	14	31 (19–46)	194	60 (55–65)	<0.001
Eczema	18	12 (8–19)	3	17 (5–41)	8	18 ( 9–32)	83	26 (21–31)	0.011

*p*-values calculated using chi-square test, \**p*-value calculated using Kruskal-Wallis test; CI: confidence interval

Class		1	2	3	4	
Class description	Total	Unspecific dry cough	Non-allergic infectious and night cough with snoring and otitis	Allergic dry night cough with snoring	Allergic cough	
	(N=531)	(N=145)	(N=18)	(N=45)	(N=323)	
	N (%)	N (%)	N (%)	N (%)	N (%)	<i>p</i> - value
Confirmed asthma <sup>1</sup>	204 (38)	38 (26)	1 (6)	9 (20)	156 (48)	< 0.001
Any confirmed or suspected asthma/asthma-like diagnosis <sup>2</sup>	370 (70)	80 (55)	8 (44)	22 (49)	260 (81)	<0.001
Any confirmed chronic cough diagnosis <sup>3</sup>	73 (14)	29 (20)	4 (22)	15 (33)	25 (8)	<0.001
Any confirmed or suspected chronic cough diagnosis <sup>4</sup>	103 (19)	41 (28)	7 (39)	20 (44)	35 (11)	<0.001
Any confirmed exercise-related problem <sup>5</sup>	22 (4)	10 (7)	2 (11)	1 (2)	9 (3)	0.059*
Any confirmed or suspected exercise-related problem <sup>6</sup>	46 (9)	20 (14)	2 (11)	2 (4)	22 (7)	0.063*
Any confirmed or suspected chronic snoring problem9	24 (5)	7 (5)	2 (11)	1 (2)	14(4)	0.453*
Confirmed rhinitis/rhino- conjunctivitis	213 (40)	11 (8)	3 (17)	15 (33)	184 (57)	<0.001
Confirmed allergic sensitisation/atopy	351 (66)	48 (33)	8 (44)	28 (62)	267 (83)	<0.001

Table 3: Diagnoses given by physicians to children in the 4 cough phenotypes (N=531)

Note: A child can have multiple diagnosis. p-values calculated using chi-square test \*p-value calculated using Fisher's exact test

<sup>1</sup> confirmed diagnosis of asthma (chronic asthma)

<sup>2.</sup> confirmed or suspected diagnosis of asthma (episodic asthma, chronic asthma, exercise-induced asthma) and asthma-like diagnosis (wheeze, recurrent bronchitis, bronchial hyperreactivity, exercise-induced wheeze)

<sup>3.</sup> any confirmed diagnosis of chronic cough, including recurrent cough of unknown aetiology, increased vulnerability to viral infections, post infectious cough, psychogenic cough, chronic obstructive rhinopathy with posterior rhinorrhoea /postnasal drip, cough hypersensitivity syndrome, protracted bacterial bronchitis, gastroesophageal reflux disease

<sup>4.</sup> *any confirmed or suspected* diagnosis of chronic cough, including recurrent cough of unknown aetiology, increased vulnerability to viral infections, post infectious cough, psychogenic cough, chronic obstructive rhinopathy with posterior rhinorrhoea /postnasal drip, cough hypersensitivity syndrome, protracted bacterial bronchitis, gastroesophageal reflux disease


<sup>5.</sup> any confirmed exercise-related problems, including dysfunctional breathing, hyperventilation syndrome, stridor, sighing, vocal cord dysfunction, induced laryngeal obstruction, deconditioning


<sup>6.</sup> any confirmed or suspected exercise-related problem: dysfunctional breathing, hyperventilation syndrome, stridor, sighing, vocal cord dysfunction, induced laryngeal obstruction, deconditioning

<sup>7</sup> any confirmed or suspected\_chronic snoring problem, including adenoid hypertrophy, tonsil hypertrophy, obstructive sleep apnea, unspecific snoring

Class	1 Unspecific dry cough (N=145)		2 Non-allergic infectious and night cough associated with snoring and otitis (N=18)		3 Allergic dry night cough with snoring (N=45)		4 Allergic cough (N=323)		
Class description									
BMI based on z-scores		· · ·							
Overweight or obese (N=521)	30	21 (15–28)	2	22 (9–47)	6	14 (6–28)	85	27 (22–32)	0.199
Spirometry parameters									
FEV1 z-score, median (N=451)	125	-0.37(-0.59– -0.10)	16	-0.18 (-1.58–0.71)	41	0.11(-0.21–0.68)	269	-0.37 (-0.50– -0.24)	0.022*
FVC z-score, median (N=440)	125	-0.26 (-0.52–0.01)	16	-0.36 (-1.55–1-07)	38	0.03 (-0.22–0.34)	261	-0.15 (-0.27–0.02)	0.800*
FEV1/FVC z-score, median (N=436)	122	-0.51 (-0.82–0.03)	16	-0.83 (-1.81–0.26)	38	0.18 (-0.26–0.93)	260	-0.41 (-0.53– -0.27)	0.003*
FEF25-75 z-score, median (N=316)	94	-0.86 (-1.280.52)	11	-1.01 (-2.40– -0.02)	25	-0.06 (-0.75–0.51)	186	-0.75 (-0.89– -0.54)	0.023*
Bronchodilator response test									
%FEV1 bronchodilator increase, median (N=239)	73	5 (3–6)	10	10 (-3 -21)	14	3 (-1–6)	142	7 (5–8)	0.183*
Positive bronchodilator reversibility§ (N=239)	13	18 (11–28)	4	40 (16–70)	2	14 (4–43)	28	20 (14–27)	0.406&
FeNO									
High FeNO <sup>+</sup> (N=479)	23	18 (12–26)	3	20 (7–47)	11	26 (15–41)	121	41 (35–47)	<0.001
FeNO ppb°, median (N=450)	116	11.0 (10.0–12.0)	13	7.0 (5.0–17.7)	37	12.8 (9.6–17.7)	284	17.9 (15.6–19.5)	<0.001*
Allergy tests¢									
Any allergy test positive (N=353)	29	31 (23–41)	7	54 (28–78)	18	56 (39–72)	151	70 (64–76)	<0.001
Total number of positive test, median (N=353)	93	0 (0–0)	13	1 (0–1)	32	1 (0–2)	215	2 (1.6–2)	<0.001*

CI: confidence interval; BMI: body mass index; we calculated BMI z-scores using reference values from the World Health Organisation; FeNO: Fractional exhaled nitric oxide, <sup>§</sup>Bronchodilator reversibility defined as an increase in FEV1 of 12% after the use of a short acting beta-agonist (SABA), <sup>+</sup> Definition of high FeNO depended on technique used and specified cut-offs for each centre and excluding FeNO of bad quality ° Including only those that performed an online measurement of FeNO and excluding those with a bad FeNO quality; <sup>c</sup>include positive skin prick test or specific IgE, *p*-value calculated using chi-square test, \**p*-value calculated using Kruskal-Wallis test; <sup>§</sup>*p*-value calculated using Fisher's exact test





FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; FeNO: Fractional Exhaled Nitric Oxide; ppb: parts per billion; include FeNO values measured using the online method

Class 1: Unspecific dry cough

Class 2: Non-allergic infectious and night cough with snoring and otitis

Class 2: Allergic dry night cough with snoring

Class 4: Allergic cough




Figure 3: Prognostic outcomes after 1 year for the 4 cough phenotypes

Class 1: Unspecific dry cough Class 2: Non-allergic infectious and night cough with snoring and otitis Class 3: Allergic dry night cough with snoring Class 4: Allergic cough